Final Results of a Placebo Controlled, Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS)

Drug Category: Array
Conference Category: Array
Lead Author: Fox E, et al.
Published Date: 11/10/2018
Download Link: /wp-content/uploads/2019/03/Final-E-Fox-ECTRIMS-2018-Presentation.pdf
Download Text:
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
astra-migrate-meta-layouts: set
Scroll to Top